TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                               Notice of Results 
 
05 May 2015, Cardiff - Verona Pharma plc (AIM: VRP), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
expects to announce its preliminary results for the year ended 31 December 2014 
on Tuesday 12 May 2015. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                               Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer 
 
FTI Consulting                                  Tel: +44 (0)20 3727 1000 
Julia Phillips / Simon Conway 
 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value. This includes the 
very significant markets for COPD and asthma maintenance therapy. The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
 
 
END
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Verona Pharma Charts.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Verona Pharma Charts.